A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of Small Molecule KIO-301 Administered Intravitreally to Patient s With Retinitis Pigmentosa (ABACUS)
Condition: Retinitis Pigmentosa Intervention: Drug: KIO-301 Sponsor: Kiora Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials